B tier · viable
Survodutide has a positive, NEJM-published phase 3 obesity trial and FDA breakthrough therapy designation for MASH, but its weight-loss effect trails tirzepatide and retatrutide, gastrointestinal adverse events reached 90% at the top dose, and it remains unapproved.
survodutide
Survodutide is an investigational once-weekly glucagon and GLP-1 receptor dual agonist that reported up to 16.6% mean weight reduction over 76 weeks in the phase 3 SYNCHRONIZE-1 trial. It holds FDA breakthrough therapy designation for MASH with fibrosis but has no marketing authorisation, and its efficacy sits below the leading dual and triple agonists.
the explanation
Survodutide targets two hormone receptors, one that reduces appetite and one that helps the liver burn fat, and it produced around 13 to 17 percent weight loss depending on how the results are counted. It is still experimental, and almost everyone on the higher dose reported stomach side effects.
regulatory status
Investigational — not approved (as of July 2026)
No approval in any jurisdiction; FDA fast track designation granted May 2021 and breakthrough therapy designation September 2024 for MASH with fibrosis.
how it works · proposed mechanism
Survodutide pairs GLP-1 appetite suppression with glucagon-driven hepatic lipid oxidation.
GLP-1 arm controls intake
GLP-1 receptor agonism reduces appetite and slows gastric emptying, providing the primary weight-loss mechanism. It also counterbalances glucagon's tendency to raise blood glucose.
Glucagon arm targets liver fat
Glucagon receptor activation increases hepatic fatty acid oxidation and reduces steatosis directly, independent of weight loss. This is the rationale for developing survodutide primarily in metabolic liver disease.
Visceral and ectopic fat
MRI substudies in SYNCHRONIZE-1 reported visceral adipose reductions of up to 34.0% and relative liver fat reductions of up to 63.1%. These compartment-specific effects exceed what body weight change alone would predict.
Tolerability is the constraint
Gastrointestinal adverse events were reported in 81% and 90% of the 3.6 mg and 6.0 mg arms versus 48% on placebo in SYNCHRONIZE-1. These were characterised as mild to moderate, and no deaths occurred.
what’s reported
evidence shape
5 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Survodutide's headline 16.6% weight loss is the efficacy-estimand figure; the treatment-policy analysis reported by the American College of Cardiology was closer to 12–13% versus 5% on placebo, materially below tirzepatide and retatrutide. Gastrointestinal adverse events affected 90% of participants at the 6.0 mg dose, which is a substantial tolerability burden for a mid-pack efficacy result.
key published findings
- SYNCHRONIZE-1 (n=725, 76 weeks, 116 sites in 14 countries) reported up to 16.6% mean weight reduction with survodutide versus 3.2% with placebo (p<0.0001), published in NEJM in June 2026.
- SYNCHRONIZE-1 reported ≥5% weight reduction in 73% (3.6 mg) and 72% (6.0 mg) of participants versus 46% on placebo (p≤0.0001 for both).
- SYNCHRONIZE-MASLD (n=218, 48 weeks) reported up to 12.2% weight loss versus 1.0% on placebo, with 84.2% achieving ≥30% relative liver fat reduction and 61.0% reaching liver fat content below 5%.
- SYNCHRONIZE-1 MRI substudies reported relative liver fat reduction up to 63.1% and visceral adipose tissue reduction up to 34.0% from baseline.
- SYNCHRONIZE-1 reported mild-to-moderate gastrointestinal adverse events in 81% (3.6 mg) and 90% (6.0 mg) versus 48% on placebo, with no deaths.
limitations of the evidence
- No head-to-head trial against tirzepatide or semaglutide exists, so relative positioning rests on cross-trial comparison, which is unreliable given differing populations and estimands.
- The pivotal MASH histology trial has not reported, so the breakthrough therapy designation is not yet backed by fibrosis-endpoint data.
- No cardiovascular outcomes trial has been completed, and published pharmacokinetic parameters including terminal half-life are not readily available in peer-reviewed form.
identity
| full name | Survodutide (BI 456906, glucagon/GLP-1 receptor dual agonist) |
| category | Metabolic |
| modality | peptide |
| formula | C192H289N47O61 |
| cas | 2805997-46-8 |
laboratory handling
| storage | Lyophilised material is typically stored at −20 °C in desiccated, light-protected vials; reconstituted solutions are generally kept at 2–8 °C for short-term laboratory use or aliquoted at −80 °C for longer storage. |
| solubility | Laboratory stocks are commonly reconstituted in bacteriostatic or sterile water; DMSO is used for in vitro assay preparations. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
5 citedBoehringer Ingelheim · 2026 · official
NEJM / American College of Cardiology · 2026 · peer-reviewed
Diabetes, Obesity and Metabolism · 2026 · peer-reviewed
Journal of Hepatology · 2024 · peer-reviewed
BioPharm International · 2026 · review
others in Metabolic